Pinney Associates

Executive Summary

Pinney Associates is a specialized consulting firm that guides pharmaceutical and consumer healthcare companies through complex regulatory and development landscapes, with a particular focus on Rx-to-OTC switch programs. Founded in 1994 and headquartered in Bethesda, Maryland, the firm leverages deep expertise in regulatory affairs, behavioral science, and clinical development to help clients achieve marketplace success. Pinney Associates is recognized for its leadership in major public health switches, including the first OTC oral contraceptive (Opill) and an OTC naloxone spray (Narcan). The company's reputation as a trusted advisor in drug development and regulatory affairs positions it as a key partner for companies seeking to navigate FDA requirements and bring products to market. Looking ahead, Pinney Associates is well-positioned to benefit from the growing trend of prescription-to-OTC switches, driven by consumer demand for greater access to healthcare products and FDA initiatives to encourage self-care. The firm's expertise in behavioral science and clinical trial design is critical for designing studies that demonstrate safe and effective OTC use. As the landscape for OTC switches expands to include additional therapeutic categories—such as contraceptives, addiction treatments, and chronic disease management—Pinney Associates is likely to see increased demand for its consulting services. However, as a private company, its financial performance is not publicly disclosed, and its growth is inherently tied to the success of its clients' regulatory submissions.

Upcoming Catalysts (preview)

• Q4 2026FDA Approval of a Major Rx-to-OTC Switch Client Product60% success
• Q2 2027Announcement of Strategic Partnership with a Top Pharma Company for an OTC Switch Portfolio50% success
• Q3 2026Publication of Landmark Whitepaper on OTC Switch Innovation and Consumer Safety80% success